Keystone Symposia

Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2020



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Obesity and NAFLD: Mechanisms and Therapeutics (B3)


Organizer(s) Rebecca A. Haeusler, Shingo Kajimura and Alexei Kharitonenkov
February 23—27, 2020
Fairmont Banff Springs • Banff, AB Canada
Discounted Abstract Deadline: Oct 23, 2019
Abstract Deadline: Nov 21, 2019
Scholarship Deadline: Oct 23, 2019
Discounted Registration Deadline: Dec 19, 2019

Sponsored by AstraZeneca, Gilead Sciences, Inc., Merck & Co., Inc. and Novo Nordisk A/S

Summary of Meeting:
Energy metabolism underlies all facets of human health. With the rates of obesity and nonalcoholic fatty liver disease (NAFLD) surging, understanding how energy metabolism is governed in healthy and diseased states is of the utmost concern. The focus of this Keystone Symposia is to bring obesity and NAFLD disease researchers together to identify metabolic disease factors and future directions. Halting the progression of NAFLD into nonalcoholic steatohepatitis (NASH) is considered an unmet need in human health. Therefore, the conference program is designed to discuss both the regulatory elements driving the progression of obesity and NAFLD and the metabolic underpinnings of NASH. The program also includes sessions on metabolites, hormones, and cellular signaling pathways and features cutting edge therapeutic approaches for obesity and NASH. This conference will bring together scientists and physicians specializing in basic, translational, and clinical research, as well as industry scientists, to create a robust exchange of ideas on how to move the field forward.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, February 23 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 27 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 28 in order to fully experience the meeting.

SUNDAY, FEBRUARY 23

16:00—20:00
Arrival and Registration

Van Horne Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Van Horne Foyer

MONDAY, FEBRUARY 24

07:00—08:00
Breakfast

Van Horne B/C
08:00—09:00
Welcome and Keynote Address

Van Horne A
* Rebecca A. Haeusler, Columbia University, USA

Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA
The Fourth Dimension of Obesity and NAFLD

09:00—11:30
New Pathways in Hepatic Metabolism

Van Horne A
* Maaike Oosterveer, University Medical Center Groningen, Netherlands

Kun-Liang Guan, University of California, San Diego, USA
The Hippo Pathway in Metabolism and Organ Growth

Coffee Break

Hannele Yki-Järvinen, University of Helsinki, Finland
Function of the PNPLA3 I148M Gene Variant in the Human Liver

Mark A. Herman, Duke University Medical Center, USA
Molecular Aspects of Fructose-Induced Metabolic Dysregulation

Lei Yin, University of Michigan Medical School, USA
Short Talk: DDB1 E3 Ligase Links Dietary Fructose Intake and ChREBP Protein Stabilization and Enhanced De Novo Lipogenesis via CRY1 Degradation

Jennifer L. Estall, Institut de Recherches Cliniques de Montréal, Canada
Short Talk: Glucagon Enhances Insulin-Mediated Suppression of Gluconeogenesis by Regulating the IRS1:IRS2 Ratio via PGC1A

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Van Horne B/C
13:00—22:00
Poster Viewing

Van Horne B/C
14:30—16:30
Career Roundtable
Interested participants must sign up at the registration desk on a first-come, first-serve basis. Maximum attendance: 60.

DC Coleman
Claudio J. Villanueva, University of California, Los Angeles, USA

Alan Morris, Nature Reviews Endocrinology, Germany

Yaron Rotman, NIDDK, National Institutes of Health, USA

Jun Wu, University of Michigan, USA

Silvia Corvera, University of Massachusetts Medical School, USA

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Mitochondrial Function in Energy Balance and Metabolic Disease

Van Horne A
* Shingo Kajimura, University of California, San Francisco, USA

Brian N. Finck, Washington University School of Medicine, USA
Targeting Mitochondrial Intermediary Metabolism to Treat NAFLD

Maren C. Podszun, NIDDK, National Institutes of Health, USA
Short Talk: Vitamin E Treatment in NAFLD Reveals Novel Pathway: Oxidative Stress Drives De-Novo Lipogenesis Through S1P/S2P Proteases

Douglas G. Mashek, University of Minnesota, USA
Lipid Droplet Signaling as a Driver of Mitochondrial Metabolism

Jun Wu, University of Michigan, USA
Nicotinic Acetylcholine Receptors in Energy Metabolism

Lawrence Kazak, McGill University, Canada
Short Talk: Creatine Energetics in Brown Fat Controls Energy Expenditure through Creatine Kinase B-Type

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Van Horne B/C
19:30—22:00
Poster Session 1

Van Horne B/C

TUESDAY, FEBRUARY 25

07:00—08:00
Breakfast

Van Horne B/C
08:00—11:00
Metabolites Mediating Tissue Crosstalk

Van Horne A
Christopher B. Newgard, Duke University Medical Center, USA
Hepatic Metabolic Regulatory Nodes Linked to Cardiometabolic Diseases

Claudio J. Villanueva, University of California, Los Angeles, USA
Adipose-Liver Crosstalk and Adaptive Thermogenesis

Coffee Break

Rebecca A. Haeusler, Columbia University, USA
Bile Acid Regulation of Metabolism

Annelise Poss, University of Utah, USA
Short Talk: Ceramides as Lipotoxic Mediators of Non-Alcoholic Fatty Liver Disease and Steatohepatitis

* James C. Lo, Weill Cornell Medicine, USA
Short Talk: An Adipose Regulator of Beta Cell Failure

Maaike Oosterveer, University Medical Center Groningen, Netherlands
Short Talk: Hepatic ChREBP Activation Limits NAFLD Development in a Mouse Model for GSD Ia

Kirk M. Habegger, University of Alabama, Birmingham, USA
Short Talk: Title to be Announced

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Van Horne B/C
13:00—22:00
Poster Viewing

Van Horne B/C
14:30—16:30
Workshop 1: Late-Breaking Research in Obesity and NAFLD

Van Horne A
* Claudio J. Villanueva, University of California, Los Angeles, USA

Andrea Galmozzi, The Scripps Research Institute, USA
Intracellular Heme Trafficking in Adipocytes Regulates Energy Homeostasis

Lucia Korinkova, Czech Academy of Sciences, Czech Republic
Impact of Lipidized Prolactin-Releasing Peptide Treatment on Metabolic Syndrome and Leptin-Related Signaling Pathways in Three Mouse Models

Iichiro Shimomura, Osaka University, Japan
Action Mechanism of High-Molecular Weight Multimer Adiponectin – Possible Role of Stem Cells, T-Cadherin, and Exosomes for Organ Protections

Mohammad Abu Odeh, University of California, San Diego, USA
FGF21 Acts Locally on the Adipose Tissue to Induce Weight Loss

Ludger Scheja, University Medical Center Hamburg-Eppendorf, Germany
The Role of the Alternative Pathway-Derived Bile Acids in NAFLD Progression

Abraham Stijn Meijnikman, Amsterdam University Medical Center, Netherlands
Hyperinsulinemia, a Key Player in Visceral Adipose Tissue and Hepatic Cellular Senescence

Yohei Kanamori, Nagoya University, Japan
Role of Iron in the Emergence of Proinflammatory and Profibrotic Macrophages in a Mouse Model of Nonalcoholic Steatohepatitis

WonGun Choi, Korea Advanced Institute of Science and Technology, South Korea
The Role of Serotonin Signaling through HTR2A/2B in Visceral Adipose Tissue

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Drivers of NAFLD and Dyslipidemia in Obesity

Van Horne A
* Masahiro Koseki, Osaka University, Japan

Elizabeth J. Parks, University of Missouri, USA
Liver Metabolic Flux in NAFLD and NASH

Greg Steinberg, McMaster University, Canada
Cellular Energy Sensing and Metabolism: Implications for Treating NAFLD

Lale Ozcan, Columbia University, USA
Glucagon-Mediated Regulation of Cholesterol Metabolism

Onno Holleboom, Amsterdam UMC, Netherlands
Short Talk: Deficiency of V-ATPase Assembly Factors TMEM199 and CCDC115 Results in Hepatic Steatosis and Hyperlipidemia and May Affect Fusion of Lipid Droplets and Lysosomes

Maria Chondronikola, University of California, Davis, USA
Short Talk: Brown Adipose Tissue is Linked to Very-Low-Density Lipoprotein Triglyceride Metabolism in People

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Van Horne B/C
19:30—22:00
Poster Session 2

Van Horne B/C

WEDNESDAY, FEBRUARY 26

07:00—08:00
Breakfast

Van Horne B/C
08:00—11:15
Obesity Pathogenesis and New Protein Therapeutic Strategies

Van Horne A
* Raymond E. Soccio, University of Pennsylvania, USA

Alexei Kharitonenkov, Novo Nordisk, USA
Novel FGF21 Variants

Hank Mansbach, 89bio, USA
BIO89-100, a Long-Acting FG21 Analog, for Treatment of NASH and Cardio-Metabolic Disorders

Coffee Break

Timothy Rolph, Akero Therapeutics, Inc., USA
Short Talk: AKR-001, a Long-Acting, Degradation-Resistant FGF21 Analog, Elicits Sustained Improvements in Markers of Glycemic Control and Lipid Metabolism in a 4-Week, Multiple Ascending Dose Study

Maria E. Wilson, Genentech, Inc., USA
Short Talk: An Anti-FGFR1/KLB Bispecific Antibody Improves Lipid Profile, Markers of Fibrogenesis, and Liver Health in Patients with Type 2 Diabetes (T2DM) and Decreases Hepatic Fat in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

Lotte Bjerre Knudsen, Novo Nordisk A/S, Denmark
GLP-1 Receptor Agonists: Mechanisms Relevant for the Treatment of Obesity and NASH

Asger Bach Lund, University of Copenhagen, Denmark
Short Talk: The Effects of GIP on Food Intake, Energy Expenditure and Plasma Glucose in Patients with Type 2 Diabetes Treated with a Long-acting GLP-1 Receptor Agonist

Bruce L. Riser, BLR Bio, USA
Short Talk: CCN3-Based Peptide Inhibits/Reverses Liver Injury in a Mouse Model of Diabetes and Obesity

Magdalene K. Montgomery, University of Melbourne, Australia
Short Talk: Arylsulfatase A (ARSA) is a Novel NASH-Regulated Hepatokine and Potent Regulator of Glycaemic Control

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Van Horne B/C
13:00—22:00
Poster Viewing

Van Horne B/C
16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Pathogenesis of NASH and Liver Fibrosis

Van Horne A
* Yaron Rotman, NIDDK, National Institutes of Health, USA

Bart Staels, Institut Pasteur de Lille, Université Lille, France
Pathways in the Transition of Fatty Liver to Active Disease NASH

Utpal B. Pajvani, Columbia University Medical Center, USA
Hepatocyte Jagged-Notch Signaling Induces Fibrosis in NASH

Anna Mae Diehl, Duke University, USA
Fixing Fatty Livers

Charlotte L. Scott, University of Ghent & VIB, Belgium
Short Talk: Lipid-Associated Stress Results in a Loss of Kupffer Cells from the Liver in NAFLD and Repopulation of the Niche by Fatty Liver Associated Macrophages

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Van Horne B/C
19:30—22:00
Poster Session 3

Van Horne B/C

THURSDAY, FEBRUARY 27

07:00—08:00
Breakfast

Van Horne B/C
08:00—11:00
Adipose Tissue and Organismal Energy Balance

Van Horne A
* Christian Wolfrum, ETH Zürich, Switzerland

Shingo Kajimura, University of California, San Francisco, USA
The Roles of Brown Adipose Tissue Beyond Thermogenesis

Karine Clément, INSERM / Sorbonne Universite, France
Origins of Adipose Tissue Fibrosis

Coffee Break

Alexander S. Banks, Harvard Medical School, USA
Obesity-Linked PPARgamma S273 Phosphorylation Promotes Insulin Resistance through Growth Differentiation Factor 3

Silvia Corvera, University of Massachusetts Medical School, USA
Mechanisms Controlling Number and Type of Adipocytes

Joerg Heeren, University Medical Center Hamburg-Eppendorf, Germany
Short Talk: Endothelial Lysosomal Acid Lipase Deficiency Impairs White Adipose Tissue Browning

Alexander Paul Sakers, University of Pennsylvania, USA
Short Talk: Lineage Specification of Perivascular Thermogenic Adipocytes

11:00—17:00
On Own for Lunch

14:30—16:30
Workshop 2: Late-Breaking Drug Targets

Van Horne A
* Shirly Pinto, Kallyope, USA

Victor Leonard Schuster, Albert Einstein College of Medicine, USA
Inhibiting the Prostaglandin Transporter PGT Induces Non-Canonical Thermogenesis at Thermoneutrality

Cecile Vernochet, Pfizer, USA
Adipose GI Signaling is Essential for Liver Fat and Whole Body Glucose Homeostasis

Shengping Wang, Johnson and Johnson, USA
Weight Loss Via Caloric Restriction Resolves Non-Alcoholic Steatohepatitis (NASH) in Cynomolgus Monkeys

Eva C. Thoma, Insphero AG, Switzerland
Establishment of a 3D Human NASH Model for High-Throughput Drug Efficacy Testing

Caslin Anne Gilroy, University of California at Berkeley, USA
The Metabolic microRNA miR-128-1 as a Therapeutic Target for the Treatment of NASH

Jean-Francois Thibodeau, Liminal R&D BioSciences Inc., Canada
PBI-4050: A Free Fatty Acid Mimetic for the Treatment of NAFLD

Jerome Deval, Aligos Therapeutics, USA
Preclinical Development of ALG-055009 as a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of NASH

Jin Zhou, Duke-NUS Medical School, Singapore
Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Non-Alcoholic Steatohepatitis (NASH)

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—18:45
Obesity & NAFLD: Bridging Basic Discoveries and Clinical Application

Van Horne A
* Rebecca A. Haeusler, Columbia University, USA

Robert K. Semple, University of Edinburgh, UK
Mechanisms Linking Human Adipose Tissue, Insulin Resistance and Fatty Liver: Insights from Human Genetics

Jan Borén, University of Gothenburg, Sweden
Novel Interventions for NAFLD

Brian Finan, Novo Nordisk, USA
Peptide Tri Agonists for the Treatment of Obesity and Diabetes

Emelie Barreby, Karolinska Institutet, Sweden
Short Talk: Characterization of Distinct Populations of Liver Macrophages in Obesity and Insulin Resistance

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Van Horne A
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Van Horne B/C
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Van Horne B/C

FRIDAY, FEBRUARY 28

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

AstraZeneca Gilead Sciences, Inc.
Merck & Co., Inc. Novo Nordisk A/S

We gratefully acknowledge additional support from these exhibitors at this conference:

Sable Systems International
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13DK123897-01

Funding for this conference was made possible (in part) by 1R13DK123897-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

Cayman Chemical Company Lipedema Foundation
Research Diets, Inc.
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



89bio


Novo Nordisk A/S


Pfizer Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179